CN111601819A - 一种重组人胰岛素或其类似物的前体的制备方法 - Google Patents
一种重组人胰岛素或其类似物的前体的制备方法 Download PDFInfo
- Publication number
- CN111601819A CN111601819A CN201980008838.6A CN201980008838A CN111601819A CN 111601819 A CN111601819 A CN 111601819A CN 201980008838 A CN201980008838 A CN 201980008838A CN 111601819 A CN111601819 A CN 111601819A
- Authority
- CN
- China
- Prior art keywords
- insulin
- precursor
- human recombinant
- hollow fiber
- liquor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002243 precursor Substances 0.000 title claims abstract description 73
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title claims abstract description 31
- 101000976075 Homo sapiens Insulin Proteins 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title abstract description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 192
- 108090001061 Insulin Proteins 0.000 claims abstract description 88
- 102000004877 Insulin Human genes 0.000 claims abstract description 88
- 229940125396 insulin Drugs 0.000 claims abstract description 88
- 239000007788 liquid Substances 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 55
- 239000012510 hollow fiber Substances 0.000 claims abstract description 35
- 238000000855 fermentation Methods 0.000 claims abstract description 34
- 230000004151 fermentation Effects 0.000 claims abstract description 34
- 239000000706 filtrate Substances 0.000 claims abstract description 26
- 238000005119 centrifugation Methods 0.000 claims abstract description 25
- 239000012528 membrane Substances 0.000 claims abstract description 18
- 238000001914 filtration Methods 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims description 29
- 241000282414 Homo sapiens Species 0.000 claims description 25
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 21
- 238000005406 washing Methods 0.000 claims description 15
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 12
- 238000010828 elution Methods 0.000 claims description 11
- 238000011068 loading method Methods 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 10
- 239000007974 sodium acetate buffer Substances 0.000 claims description 10
- 239000004026 insulin derivative Substances 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 239000002131 composite material Substances 0.000 claims description 7
- 238000001976 enzyme digestion Methods 0.000 claims description 7
- 239000003929 acidic solution Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 241001052560 Thallis Species 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 238000005341 cation exchange Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 238000005374 membrane filtration Methods 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000012670 alkaline solution Substances 0.000 claims description 3
- 239000003637 basic solution Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000011067 equilibration Methods 0.000 claims description 3
- MCHZKGNHFPNZDP-UHFFFAOYSA-N 2-aminoethane-1,1,1-triol;hydrochloride Chemical compound Cl.NCC(O)(O)O MCHZKGNHFPNZDP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 239000007986 glycine-NaOH buffer Substances 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 238000012799 strong cation exchange Methods 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 17
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 108091029865 Exogenous DNA Proteins 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000003960 organic solvent Substances 0.000 abstract description 3
- 230000003321 amplification Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000012986 modification Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 241000235058 Komagataella pastoris Species 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 238000001471 micro-filtration Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000012501 chromatography medium Substances 0.000 description 4
- 238000005352 clarification Methods 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 241001506991 Komagataella phaffii GS115 Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000011093 media selection Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/06—Specific process operations in the permeate stream
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2688—Biological processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2697—Chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/10—Cross-flow filtration
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种重组人胰岛素或其类似物的前体的制备方法，包括a.菌体发酵，将发酵液进行连续流离心，收集清液；b.将步骤a中的清液经过中空纤维膜过滤，收集滤液；c.将步骤b中的滤液通过层析柱进行纯化。该方法具有步骤精简、易放大生产、无有机溶剂、收率高等优点，胰岛素前体纯度可高于90％，宿主细胞蛋白去除率高于90％，外源性DNA去除率达到89％及以上、低于0.1ng/mg。
Description
PCT国内申请，说明书已公开。
Claims (17)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018105079287 | 2018-05-24 | ||
| CN201810507928 | 2018-05-24 | ||
| PCT/CN2019/088083 WO2019223752A1 (zh) | 2018-05-24 | 2019-05-23 | 一种重组人胰岛素或其类似物的前体的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111601819A true CN111601819A (zh) | 2020-08-28 |
Family
ID=68616602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980008838.6A Pending CN111601819A (zh) | 2018-05-24 | 2019-05-23 | 一种重组人胰岛素或其类似物的前体的制备方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210198311A1 (zh) |
| EP (1) | EP3805257A4 (zh) |
| JP (1) | JP2021524464A (zh) |
| KR (1) | KR20210016400A (zh) |
| CN (1) | CN111601819A (zh) |
| AU (1) | AU2019272401A1 (zh) |
| BR (1) | BR112020023485A2 (zh) |
| CA (1) | CA3100869A1 (zh) |
| TW (1) | TWI742377B (zh) |
| WO (1) | WO2019223752A1 (zh) |
| ZA (1) | ZA202007812B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020097876A1 (zh) * | 2018-11-15 | 2020-05-22 | 中国科学院大连化学物理研究所 | 一种多级孔ts-1分子筛的制备方法 |
| EP3862320A4 (en) * | 2018-11-15 | 2021-11-03 | Dalian Institute Of Chemical Physics, Chinese Academy Of Sciences | METHOD OF PREPARING A TS-1 HIERARCHICAL MOLECULAR SIEVE |
| CN113563413A (zh) * | 2021-08-17 | 2021-10-29 | 汉肽生物医药集团有限公司 | 毕赤酵母高密度发酵过程中色素的去除方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101589058A (zh) * | 2006-10-20 | 2009-11-25 | 株式会社未来创药研究所 | 包含抗hb-egf抗体作为活性成分的癌症治疗剂 |
| CN101717442A (zh) * | 2008-10-09 | 2010-06-02 | 重庆富进生物医药有限公司 | 聚乙二醇化重组人DesB30胰岛素及其制备方法和应用 |
| CN102439154A (zh) * | 2009-03-12 | 2012-05-02 | 比格科技私人有限公司 | 一种多核苷酸和多肽链序列及其方法 |
| CN107446039A (zh) * | 2016-05-31 | 2017-12-08 | 江苏恒瑞医药股份有限公司 | 一种人胰岛素类似物前体及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR910700262A (ko) | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
| CN1059703C (zh) * | 1993-04-10 | 2000-12-20 | 北京大学 | 人胰岛素前体基因在大肠杆菌中的直接表达及后加工方法 |
| UA45321C2 (uk) | 1993-09-17 | 2002-04-15 | Ново Нордіск А/С | Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету |
| US6268487B1 (en) * | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
| KR100253916B1 (ko) | 1997-12-29 | 2000-05-01 | 김충환 | 사람 인슐린 전구체의 제조방법 |
| AU2003266216A1 (en) * | 2002-09-25 | 2004-04-19 | Novo Nordisk A/S | Purification process comprising microfiltration at elevated temperatures |
| EP1567657A1 (en) * | 2002-11-26 | 2005-08-31 | Novo Nordisk A/S | Process for purifying a fermentation-derived product |
| PL2107069T3 (pl) | 2003-08-05 | 2013-06-28 | Novo Nordisk As | Nowe pochodne insuliny |
| DK1969004T3 (da) | 2005-12-28 | 2011-11-28 | Novo Nordisk As | Insulinsammensætninger og metode til at lave en sammensætning |
| JP6249773B2 (ja) | 2010-05-10 | 2017-12-20 | ノヴォ ノルディスク アー／エス | インスリン−亜鉛錯体の調製方法 |
| WO2014122651A1 (en) * | 2013-02-07 | 2014-08-14 | Valin Technologies Ltd. | Process for preparing insulin |
| WO2014122653A1 (en) * | 2013-02-07 | 2014-08-14 | Valin Technologies Ltd. | Process for preparing insulin |
| EP3268384B1 (en) * | 2015-03-10 | 2021-11-03 | Merck Sharp & Dohme Corp. | Process for preparing recombinant insulin using microfiltration |
| CN106282274B (zh) | 2015-06-29 | 2021-05-11 | 宜昌东阳光长江药业股份有限公司 | 一种胰岛素前体蛋白的毕赤酵母高密度发酵方法 |
| CN105153294B (zh) | 2015-08-31 | 2019-02-12 | 济南康和医药科技有限公司 | 一种重组胰岛素及胰岛素类似物前体纯化方法 |
| CN105111304B (zh) * | 2015-09-30 | 2018-12-14 | 山东阿华生物药业有限公司 | 重组人胰岛素前体的纯化和酶切转换方法 |
| CN106554410B (zh) * | 2016-06-02 | 2019-11-26 | 陕西东大生化科技有限责任公司 | 一种重组人源胶原蛋白及其编码基因和制备方法 |
| TWI747929B (zh) | 2016-08-02 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人胰島素或其類似物的醯化衍生物 |
-
2019
- 2019-05-23 KR KR1020207037109A patent/KR20210016400A/ko not_active Application Discontinuation
- 2019-05-23 AU AU2019272401A patent/AU2019272401A1/en not_active Abandoned
- 2019-05-23 CN CN201980008838.6A patent/CN111601819A/zh active Pending
- 2019-05-23 WO PCT/CN2019/088083 patent/WO2019223752A1/zh unknown
- 2019-05-23 JP JP2020565286A patent/JP2021524464A/ja not_active Withdrawn
- 2019-05-23 EP EP19808332.1A patent/EP3805257A4/en not_active Withdrawn
- 2019-05-23 TW TW108117907A patent/TWI742377B/zh not_active IP Right Cessation
- 2019-05-23 BR BR112020023485-0A patent/BR112020023485A2/pt not_active IP Right Cessation
- 2019-05-23 CA CA3100869A patent/CA3100869A1/en active Pending
- 2019-05-23 US US17/057,609 patent/US20210198311A1/en not_active Abandoned
-
2020
- 2020-12-15 ZA ZA2020/07812A patent/ZA202007812B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101589058A (zh) * | 2006-10-20 | 2009-11-25 | 株式会社未来创药研究所 | 包含抗hb-egf抗体作为活性成分的癌症治疗剂 |
| CN101717442A (zh) * | 2008-10-09 | 2010-06-02 | 重庆富进生物医药有限公司 | 聚乙二醇化重组人DesB30胰岛素及其制备方法和应用 |
| CN102439154A (zh) * | 2009-03-12 | 2012-05-02 | 比格科技私人有限公司 | 一种多核苷酸和多肽链序列及其方法 |
| CN107446039A (zh) * | 2016-05-31 | 2017-12-08 | 江苏恒瑞医药股份有限公司 | 一种人胰岛素类似物前体及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 吴梧桐主编: "《生物制药工艺学》", 31 August 2015, 中国医药科技出版社, pages: 540 * |
| 董鹏: "重组人胰岛素原在毕赤酵母中的表达及分离纯化的研究", 《中国优秀硕士学位论文全文数据库》, no. 11, 15 November 2006 (2006-11-15), pages 6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI742377B (zh) | 2021-10-11 |
| WO2019223752A1 (zh) | 2019-11-28 |
| EP3805257A1 (en) | 2021-04-14 |
| CA3100869A1 (en) | 2019-11-28 |
| KR20210016400A (ko) | 2021-02-15 |
| US20210198311A1 (en) | 2021-07-01 |
| EP3805257A4 (en) | 2022-03-16 |
| ZA202007812B (en) | 2021-10-27 |
| BR112020023485A2 (pt) | 2021-03-30 |
| JP2021524464A (ja) | 2021-09-13 |
| AU2019272401A1 (en) | 2021-01-14 |
| TW202012433A (zh) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111601819A (zh) | 一种重组人胰岛素或其类似物的前体的制备方法 | |
| CN102532254B (zh) | 一种从水稻种子中分离纯化重组人血清白蛋白的方法 | |
| DE69927013T2 (de) | Effiziente reinigung von adenovirus | |
| CN114456940B (zh) | 一种提高大肠杆菌裂解过程中质粒稳定性的方法 | |
| CN110628744A (zh) | 一种从浓香型大曲中分离纯化酯化酶的方法 | |
| CN104418774A (zh) | 栝楼瓤微生物发酵提取l-瓜氨酸的方法 | |
| CN117512031B (zh) | 一种肺炎球菌荚膜多糖的纯化方法 | |
| CN116970095A (zh) | 一种肺炎球菌荚膜多糖的制备方法 | |
| CN106366200B (zh) | 制备重组葡激酶-水蛭素融合蛋白的方法 | |
| CN1336434A (zh) | 胰激肽原酶的制备及其亲和层析纯化方法 | |
| CN107033236A (zh) | 一种从酵母发酵液中分离人血白蛋白的混合模式层析方法 | |
| CN103642794B (zh) | 一种大量制备BCG-CpG-DNA的方法 | |
| US7439337B2 (en) | Three-phase partitioning method for purifying a protein | |
| CN114885608A (zh) | 纯化重组蛋白的方法 | |
| CN108570098A (zh) | 一种百日咳多种抗原成分的分离纯化方法 | |
| CN113913415B (zh) | 一种分离人尿激肽原酶和凝血酶调节蛋白的方法 | |
| Sinha et al. | Advances in downstream processing techniques | |
| RU2253676C2 (ru) | Способ получения полигалактуроназного ферментного препарата | |
| CN217773806U (zh) | 一种唾液酸的提取浓缩装置 | |
| RU2230119C1 (ru) | Способ получения дисахарида | |
| CN110343170B (zh) | 纤溶酶抑制剂rPI-T1的分离纯化方法 | |
| CN108017688B (zh) | 一种目的蛋白的纯化方法 | |
| CN112812142A (zh) | 一种单唾液酸四己糖神经节苷脂钠的精制方法 | |
| CN113563413A (zh) | 毕赤酵母高密度发酵过程中色素的去除方法 | |
| CN118240054A (zh) | 一种纯化Sox2蛋白的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40036083 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200828 |